Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million Tuesday in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through an NDA submission.